Resistance to ibritumomab in lymphoma. ([2018])

• Record Type: Book
• Further Information: Note: Makoto Hosono, Jean-François Chatal, editors.
• Editors: Hosono, Makoto; Chatal, Jean-François, 1939-
• Contents: Intro; "Resistance to Targeted Anti-Cancer Therapeutics": Aims and Scope; Preface; Biography of Series Editor; Acknowledgments; Contents; Clinical Use and Efficacy of Ibritumomab in B Cell Lymphoma; 1 Introduction; 2 Characteristics of Zevalin; 3 Treatment Schedule and Dosage of Zevalin; 4 Patient Eligibility; 5 Zevalin in Relapse or Refractory Patients; 6 Zevalin in Frontline Therapy; 7 Toxicities and Safety Profile; 8 Factor Associated with Effects of Zevalin; 9 Future Aspects; References; Biology and Pathology of B-Cell Lymphoma; 1 Introduction; 2 Cellular Origin of B-Cell Lymphomas. 3 Features of Ibritumomab4 A Model of Theranostic Approach; 5 Enhancing Efficacy of Ibritumomab Tiuxetan; 6 Conclusion; References; Radiological Evaluation of Response and Resistance of Ibritumomab; 1 Introduction; 2 Evaluation of FDG-PET/CT for Monitoring the Response to RIT; 2.1 FDG-PET/CT Imaging; 3 Summary of the Results; 4 Discussion; 5 Conclusions; References; Characteristics of Ibritumomab as Radionuclide Therapy Agent; 1 Introduction; 2 CD 20: B-Cell Antigen; 3 mAb Targeting CD20; 4 Ibritumomab Tiuxetan Coupled with Radioisotopes; 4.1 Ibritumomab; 4.2 Tiuxetan; 4.3 Radionuclides. 5 Yttrium-90 (90Y)6 Indium-111 (111In); 7 Preclinical Investigation of 90Y-/111In-Ibritumomab Tiuxetan; 7.1 In Vitro Studies; 7.2 Ex Vivo/In Vivo Studies; 8 Imaging and Therapy Protocol; 8.1 Preparation of 90Y-Ibritumomab Tiuxetan; 8.2 Schedule of 90Y-Ibritumomab Tiuxetan Therapy; 9 Perspectives and Conclusion; References; Resistance and Heterogeneity of Intratumoral Antibody Distribution; 1 Introduction; 2 SPECT/CT and PET/CT System; 3 Statistical Approach Taken to Characterize Lesion's Uptake; 4 Resistance and Heterogeneity of Intratumoral Antibody Distribution. 5 Conclusions and PerspectivesReferences; Radiation Dosimetry in Ibritumomab Therapy; 1 Introduction; 2 Activity Escalation Trial and Dose Escalation Trial; 3 Dosimetry for Molecular Radiotherapy; 3.1 Quantification of Pharmacokinetics; 3.2 Kinetic Model; 3.3 Prediction of Pharmacokinetics During Therapy; 3.4 Absorbed Dose Calculations; 3.5 Treatment Planning; 3.6 Treatment and Quality Control Measurements; 3.7 Conclusion; 4 Dosimetry for Ibritumomab Tiuxetan; 5 Treatment Planning for [90Y]Ibritumomab Tiuxetan; 6 Conclusion and Outlook; References.
• Publisher Details: Cham : Springer
• Publication Date: 2018
• Copyright Date: 2018
• Extent: 1 online resource, illustrations
• Subjects: 616.99/446; Medicine; Lymphomas -- Treatment; Drug resistance in cancer cells; Oncology; HEALTH & FITNESS -- Diseases -- General; MEDICAL -- Clinical Medicine; MEDICAL -- Diseases; MEDICAL -- Evidence-Based Medicine; MEDICAL -- Internal Medicine; Drug resistance in cancer cells; Lymphomas -- Treatment; Medical -- Oncology; Oncology; Biomedicine; Cancer Research; Electronic books
• Languages: English
• ISBNs: 9783319782386
• Related ISBNs: 331978238X; 9783319782379; 3319782371
• Notes: Note: Includes bibliographical references and index.; Note: Online resource; title from PDF title page (EBSCO, viewed April 30, 2018).
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.